For example, Zhang et al. (2018) observed that Silymarin significantly inhibited the activation of NLRP3 inflammasomes in NAFLD by increasing NAD+ levels, preserving the NAD+-dependent α-tubulin deacetylase sirtuin (SIRT) 2 activity, and inhibiting acetylated α-tubulin-induced NLRP3 inflammasome activation, demonstrating the anti-inflammatory and liver-protective effects of Silibinin mainly focused on cytokine release (Zhang et al., 2018). This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.